Global Health: FY26 results approved, ₹0.50 dividend recommended, two SMPs named
Global Health · Healthcare Services
Key highlights
- Audited standalone FY26 revenue from operations ₹37,093.78 million and profit after tax ₹4,962.01 million; Q4 standalone profit after tax ₹1,241.31 million vs ₹934.12 million a year earlier
- Mr. Kedar Ashok Apte (Chief Marketing & Growth Officer) and Mr. Jagdeep Singh (General Counsel) designated SMPs w.e.f. May 14, 2026; Ms. Richa Singh resigns w.e.f. May 20, 2026
- Final dividend of Rs. 0.50 (25%) per share of face value Rs. 2 recommended for FY26, subject to shareholder approval at the AGM
Why it's rated notable: the year-on-year change is 40% (20% to 50%)
Figures checked against the filing by a second AI read, which corrected the first summary. About the business, not the share price.
Original filing
Board Meeting Outcome For Intimation Of Audited Financial Results.
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Global Health
- Capex / expansionNotableGlobal Health (Medanta) Q2 FY27 revenue up 33.6%; 500-bed Ghaziabad hospital approved
- Dividend / buyback / bonusNotableGlobal Health Ltd announces Q1 FY 2026-27 financial results and management changes
- Capex / expansionNotableGlobal Health Limited announces Q1 FY 2026-27 financial results and new appointment
- Capex / expansionNotableGlobal Health Ltd Q1 results; Chief Digital Officer named; Guwahati beds to 650
- Dividend / buyback / bonusNotableGlobal Health Limited reports Q1 FY27 results and appoints Chief Digital Officer
Other financial results filings this fortnight
- Siddhika Coatings Limited approves joint venture and announces H1 FY 2026 financials
- Financial resultsBrooks LaboratoriesBrooks Laboratories Limited announces Q2 and H1 FY2026 unaudited financial results
- Financial resultsBrooks LaboratoriesBrooks Laboratories Limited announces Q2 and H1 FY2027 financial results and divestment
- NHC Foods reports Sept 2026 quarter results, 99.98% firm stake, two appointments
- Spectrum Electrical Industries Ltd approves Q2 & H1 results for period ended September 30, 2026
- Dev Labtech Venture reports unaudited half-year results to 30 Sept 2026
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- Aster DM QualityGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.